These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 7352067)

  • 1. Incidence of hyperprolactinemia during oral contraceptive therapy.
    Reyniak JV; Wenof M; Aubert JM; Stangel JJ
    Obstet Gynecol; 1980 Jan; 55(1):8-11. PubMed ID: 7352067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins.
    Bradley DD; Wingerd J; Petitti DB; Krauss RM; Ramcharan S
    N Engl J Med; 1978 Jul; 299(1):17-20. PubMed ID: 207983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phytohemagglutin-induced lymphocyte transformation in oral contraceptive users.
    Keller AJ; Irvine WJ; Jordan J; Loudon NB
    Obstet Gynecol; 1977 Jan; 49(1):83-91. PubMed ID: 63929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative enhancement of dinitrochlorobenzene responsivity in women receiving oral contraceptives.
    Rea TH
    Arch Dermatol; 1979 Mar; 115(3):361-2. PubMed ID: 434857
    [No Abstract]   [Full Text] [Related]  

  • 5. Hemostatic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel.
    Sabra A; Bonnar J
    J Reprod Med; 1983 Jan; 28(1 Suppl):85-91. PubMed ID: 6834350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral contraceptive estrogen and plasma lipid levels.
    Hedlin A; Kuksis A; Geher K
    Obstet Gynecol; 1978 Oct; 52(4):430-5. PubMed ID: 714324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The desogestrel-ethinyl estradiol combination and overweight: current data].
    Rubio Lotvin B
    Ginecol Obstet Mex; 1995 Nov; 63():483-6. PubMed ID: 8537039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body weight change during use of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake.
    Endrikat J; Gerlinger C; Cronin M; Wessel J; Ruebig A; Rosenbaum P; Düsterberg B
    Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):199-204. PubMed ID: 11848649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [After miniaturization to the limit, a double phase estro-progestin with early reinforcement. Result of a study of a new contraceptive based on d-norgestrel].
    Soutoul JH; Renaud M; Bertrand J
    Gynecologie; 1976; 27(5):487-93. PubMed ID: 1001603
    [No Abstract]   [Full Text] [Related]  

  • 10. Oestrogen containing oral contraceptives and antithrombin III activity.
    Rákóczi I; Nagy I; Szigetvári I; Losonczy H; Hadnagy J; Gáti I
    Acta Physiol Acad Sci Hung; 1974; 45(3-4):281-6. PubMed ID: 4471272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacology of the new steroid contraceptives].
    Korkhov VV
    Akush Ginekol (Mosk); 1979 Feb; (2):5-8. PubMed ID: 371434
    [No Abstract]   [Full Text] [Related]  

  • 12. Platelet changes in women taking oral contraceptives.
    Burrow JP; Luce JK
    Postgrad Med; 1977 Aug; 62(2):52-6. PubMed ID: 882469
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacological properties of steriod contraceptives (literature survey)].
    Seĭfulla RD; Chubarova AV
    Farmakol Toksikol; 1976; 39(3):367-77. PubMed ID: 1026521
    [No Abstract]   [Full Text] [Related]  

  • 14. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative studies into effects of synthetic oestrogens and gestagens on certain serum protein fractions under standardised conditions (author's transl)].
    Klinger G; Stelzner A; Krause G; Tarnick M; Scheler R; Schubert H; Börner A; Carol W
    Zentralbl Gynakol; 1980; 102(24):1410-20. PubMed ID: 6164183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum gamma-glutamyl transpeptidase activity in viral hepatitis: suppression in pregnancy and by birth control pills.
    Combes B; Shore GM; Cunningham FG; Walker FB; Shorey JW; Ware A
    Gastroenterology; 1977 Feb; 72(2):271-4. PubMed ID: 12064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex steroids and thyroid function tests: the role of estrogen and progestogen.
    Miyamoto J
    Int J Gynaecol Obstet; 1978; 16(1):28-33. PubMed ID: 83257
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperprolactinemia and contraception: a prospective study.
    Luciano AA; Sherman BM; Chapler FK; Hauser KS; Wallace RB
    Obstet Gynecol; 1985 Apr; 65(4):506-10. PubMed ID: 3982724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene].
    Belaisch J; Hommais-loufrani B
    Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of a once-a-month oral contraceptive on serum prolactin levels].
    Jia MC; Xiao BL
    Zhonghua Fu Chan Ke Za Zhi; 1985 Mar; 20(2):113-6, 127. PubMed ID: 4006587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.